Gynecologic Oncology
Conditions
Interventions
Case series:Nil
Sponsors
The First Affiliated Hospital of He'nan University of Science and Technology
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Female aged >=18 years old, weight>30Kg; 2.Patients with advanced cervical cancer, endometrial cancer, ovarian cancer and other gynecological tumors diagnosed by histology or cytology; 3.At least one measurable lesion (spiral CT scan length of measurable lesion >=10mm or short diameter of enlarged lymph node >=15mm according to RECIST1.1); 4.The researchers determined that patients could receive Carrerizumab; 5.The patient was voluntarily treated with Carrelizumab; 6.Volunteer to join this study, sign informed consent, good compliance and cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1.Pregnant or nursing women; 2.People allergic to Carrelizumab and its accessories; 3.Patients currently participating in other clinical studies; 4.The researchers judged other circumstances not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival;time to progression;objective remission rate;disease control rate; | — |
Countries
China
Contacts
Public ContactWang Yan
The First Affiliated Hospital of He'nan University of Science and Technology
Outcome results
None listed